CYP2D6 is the principal cytochrome P450 responsible for metabolsim of the histamine H1 antagonist promethazine in human liver microsomes

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 449-457

  Nakamura, Katsunori ^a   Yokoi, Tsuyoshi ^a   Inoue, Kazuaki ^b   Shimada, Noriaki ^c   Ohashi, Noriko ^d   Kume, Toshiyuki ^d   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Homochlorcyclizine; Mequitazine; Poor metabolizer; Tandem mass spectrometry

Indexed keywords

7 ETHOXYCOUMARIN; ALIMEMAZINE; BUFURALOL; CHLORPHENIRAMINE; CHLORPROMAZINE; CLEMASTINE; COUMARIN; CYCLOSPORIN A; CYTOCHROME P450 ANTIBODY; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DIPHENHYDRAMINE; DIPHENYLPYRALINE; ENZYME ANTIBODY; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; ISOTHIPENDYL; MEQUITAZINE; OXYGENASE; PHENACETIN; PROADIFEN; PROMETHAZINE; PROPRANOLOL; QUINIDINE; SPARTEINE; SULFAPHENAZOLE; TRIPROLIDINE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME INHIBITION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ANTIBODIES; B-LYMPHOCYTES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ETHANOLAMINES; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROXYLATION; MASS SPECTROMETRY; MICROSOMES, LIVER; PROMETHAZINE;

EID: 0029798503     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00009     Document Type: Article

References (45)

1. Alhaide AA, Mustafa AA. Acceleration of rat brain beta-adrenoceplor subsensitivity following the coadministralion of histamine receptor antagonists with imipramine. Agents Actions 1989: 28, 153-158.
2. Allender WJ, Archer AW. Liquid Chromatographic analysis of promethazine and its major metabolites in human postmortem material. J Forensic Sci 1984: 29, 515-526.
3. Baker MT, Olson MJ, Wang Y, Ronnenberg WC, Johnson JT, Brady AN. Isofluran-chlorodifluoroethene interaction in human liver microsomes. Drug Metab Dispos 1995: 23, 60-64.
4. Brøsen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987: 60, 312-314.
5. Cashman JR, Yang Z, Yang L, Wrighton SA. Stereo- and Regio-selective N- and S-oxydation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab Dispos 1993: 21, 492-501.
6. Clement B Lustig KL , Ziegler M. Oxidation of desmethylprometha-zine catalyzed by pig liver flavin-containing monooxygenase. Number and nature of metabolites. Drug Metab Dispos 1993: 21, 24-29.
7. Clement BA, Beckett AH. Metabolism of promethazine in vitro. Identification of N-oxidised products. Xenobiotica 1981: 11, 609-618.
8. Cochin J, Daly JW. The use of thin layer chromatography for the analysis of drug. Identification and isolation of phenothiazine tranquilizers and of antihistaminics in body fluids and tissues. J Pharmacol Exp Ther 1963: 139, 160-165.
9. Cornish-Bowden A. Fundamentals of enzyme kinetics. London, Boston: Butterworths, 1979: 73-88.
10. Crcspi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JTM, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 1995: 5, 234-243.
11. Distlerath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation. two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985: 260, 9057-9067.
12. Eichelbaum M, Gross AS, The genetic polymorphism of debrisoquine/sparteine metabolism. New York: Pergamon Press, 1992: 625-648.
13. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck J-P, Minery P, Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryputamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994: 22, 269-274.
14. Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991: 266, 10019-10022.
15. Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986: 30, 287-295.
16. Halpern BN, Ducrot R. Recherches expérimentales sur unenouvelle série chimique de corps doués de propriétés antihista-miniques puissantes: les dérivés de la thiodiphénylamine (T.D.A.), Compat Rend Seanc Soc Biol 1946: 140, 361-365.
17. 35. Arch Int Pharmacodyn Ther 1960: 131, 309-324.
18. Hickson GB, Altemeier WA, Clayton EW. Should promethazine in liquid form be available without prescription? Pediatrics 1990: 86, 221-225.
19. 1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms, J Pharmacol Exp Ther 1995: 272, 939-944.
20. Hyland R, Gescher A, Thummel K, Schiller C, Jheeta P, Mynett K, Smith AW, Mraz J. Metabolic oxidation and toxification of N-methylformamide catalyzed by the cytochrome P450 isocnzyme CYP2E1. Mol Pharmacol 1992: 41, 259-266.
21. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987: 23, 482-485.
22. Kamataki T, Kitagawa H. Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochem Pharmacol 1973: 22, 3199-3207.
23. Kronbach T, Mathys D, Gut J, Catin T, Meyer A. High-performance liquid Chromatographie assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987: 162, 24-32.
24. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988: 43, 630-635.
25. Lowry OH, Rosebrougr NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951: 193, 265-275.
26. Nakamura K, Goto F, Ray A, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
27. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Establook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996: 6, 1-41.
28. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984: 34, 73-80.
29. Rettie AE, Korzekwa KK, Kunze KL, Lawrence RF, Eddyll AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager FW. Hydroxylation of warfarin by human liver cytochrome P-450: a role for proteins encoded by CYP2C9 in the etiology of anticoagulation drug interactions. Chem Res Toxicol 1992: 5, 54-59.
30. Robinson AE. Biotransformations in vitro undergone by phenothiazine derivatives in a liver preparation. J Pharm Pharmacol 1966: 18, 19-32.
31. Robinson AE, Beaven VH. Hydroxylation in vitro of pharmaco-logically active phenothiazine derivatives. J Pharm Pharmacol 1964: 16, 342-346.
32. Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994: 48, 2147-2156.
33. Rusiecki W, Wysocka-Paruszewska B, Excretion, distribution, and metabolism of promethazine in rats. Dissert Pharm Pharmacol 1969: 21, 73-79.
34. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metroprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991: 32, 504-507.
35. Strobl GR, Kruedener S, Stockigt J, Guengerich FP, Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P-4502D6: Molecular modeling and inhibition studies. J Med Chem 1993: 36, 1136-1145.
36. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
37. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO. Specificity of substrate and probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993: 265, 401-407.
38. Tassaneeyakul W, Birkett DJ, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994: 47, 1767-1776.
39. Taylor G, Houston JB. Simultaneous determination of promethazine and two of its circulating metabolites by high-performance liquid chromatography. J Chromatogr 1982: 230, 194-198.
40. Taylor G, Houston JB. Changes in the disposition of promethazine during multiple dosing in the rabbit. J Pharm Pharmacol 1985: 37, 245-247.
41. Taylor G, Houston JB, Shaffer J, Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous oral administration to man. Br J Clin Pharmacol 1983: 15, 287-293.
42. Yamada H, Shimizudani T, Hatsumura M, Oguri K, Yoshimura H. Metabolic formation of dimethylamine and methylamine from basic drugs containing N-methyl group: A newly established Chromatographic assay and its application to the determination of deaminase activity. Biol Pharm Bull 1993: 16, 847-851.
43. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990: 29, 1322-1329.
44. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T. A new CYP2D6 allele a nine base insertion in Exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics in press.
45. Yumibe N, Huie K, Chen KJ, Clement RP, Cayen MN. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistamic drug loratadine. Int Arch Allergy Immunol 1995: 107, 420.